Form 4: Aclaris Therapeutics COO Davis Converts RSUs

Aclaris Therapeutics' President and COO, Hugh M. Davis, converted 26,750 restricted stock units into common stock on December 2, 2025.

Summary

• Hugh M. Davis, President and COO, and a Director of Aclaris Therapeutics, Inc. (ACRS), reported a transaction on December 2, 2025.
• Davis acquired 26,750 shares of Aclaris Therapeutics common stock through the conversion of restricted stock units (RSUs).
• Following this transaction, Davis directly beneficially owns 26,750 shares of common stock.
• Davis also directly beneficially owns 80,250 restricted stock units.
• The RSUs represent a contingent right to receive one share of common stock of the Issuer.
• The remaining 80,250 RSUs vest in four equal installments on the first, second, third, and fourth anniversaries of December 2, 2024, subject to continuous service.

Sentiment

Score: 6

Explanation: The conversion of restricted stock units into common stock by a key executive and director is a routine event that increases their direct ownership, aligning their interests with shareholders. While not an open market purchase, it reflects the executive's continued stake in the company's performance, which is mildly positive.

Positives

• An insider, Hugh M. Davis (President, COO, and Director), is increasing direct ownership of common stock through RSU conversion, which aligns executive interests with shareholders.
• The conversion of restricted stock units into common stock represents a standard vesting event as part of executive compensation.

Negatives

• The transaction is a conversion of previously granted equity awards rather than an open market purchase, which would typically signal stronger conviction in the company's immediate prospects.

Risks

• The vesting of the remaining 80,250 restricted stock units is contingent upon Hugh M. Davis's continuous service with Aclaris Therapeutics, Inc.

Future Outlook

The remaining 80,250 restricted stock units held by Hugh M. Davis are scheduled to vest in four equal installments on the first, second, third, and fourth anniversaries of December 2, 2024, contingent upon his continuous service. This indicates future potential increases in his direct common stock ownership.

Industry Context

This is a routine insider transaction related to executive compensation and the vesting of equity awards. It reflects standard practices for retaining and incentivizing key management within the biotechnology or pharmaceutical sector, rather than providing specific insights into broader industry trends or the competitive landscape.

Stakeholder Impact

• Shareholders: The increase in direct common stock ownership by a key executive and director enhances the alignment of management's interests with those of the shareholders.
• Employees: The transaction reflects the ongoing execution of standard executive compensation practices, which can be a positive signal regarding employee retention strategies.

Next Steps

• Future vesting events for the remaining 80,250 restricted stock units will occur on the first, second, third, and fourth anniversaries of December 2, 2024, subject to continuous service.

Key Dates

Keywords

Aclaris Therapeutics, ACRS, Hugh M. Davis, Form 4, Insider Transaction, Restricted Stock Units, RSU conversion, Common Stock, Executive Compensation, Director, COO, President